New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For IN;HON;NXY;CEO;MCD;CLDX;ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
November 20, 2014
14:26 EDTZGNXZogenix slips after FDA approves new extended-release opioid analgesic
Shares of Zogenix, the maker of Zohydro ER, are lower in afternoon trading after the FDA approved Hysingla ER, another extended-release opioid analgesic. WHAT'S NEW: Earlier, the Food and Drug Administration announced it has approved Hysingla ER, which is an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Hysingla ER has approved labeling describing the product’s abuse-deterrent properties consistent with the FDA’s 2013 draft guidance for industry. Hysingla ER is manufactured by Purdue Pharma. WHAT'S NOTABLE: Janet Woodcock, the director of the Center for Drug Evaluation and Research, stated in a post to the "FDA Voice" blog, that the approval of Hysingla ER marks additional progress in the fight against the ongoing misuse and abuse of prescription opioids. In her blog post, Woodcock stated: "While Hysingla ER has the same active ingredient, hydrocodone, as Zohydro ER, the only other approved extended-release hydrocodone product, there are important differences between the two." Hysingla ER has approved abuse-deterrent labeling, while Zohydro ER does not, Woodcock noted. The CDER director also stated that the FDA has not yet determined whether Hysingla ER will prove to be safer than Zohydro ER. PRICE ACTION: In afternoon trading, shares of Zogenix slipped 1.7% to $1.18.
November 19, 2014
10:34 EDTMCDOptions with increasing implied volatility
Subscribe for More Information
08:28 EDTMCDMcDonald's repeats intent to to return $18B-$20B to shareholders over 2014-16
Subscribe for More Information
07:10 EDTHONHoneywell management to meet with Sterne Agee
Subscribe for More Information
05:44 EDTMCDStocks with implied volatility movement; MCD KO
Subscribe for More Information
05:42 EDTCEOCNOOC makes mid-sized new discovery in Eastern South China Sea
CNOOC announced that the company made a mid-sized new discovery Lufeng14-4 in the Eastern South China Sea. The Lufeng14-4 structure is located in Lufeng Sag in the Pearl River Mouth Basin of the South China Sea with an average water depth of 145 meters. The discovery well Lufeng14-4-1 was drilled and completed at a depth of 4,098 meters and encountered oil pay zones with a total thickness of approximately 150 meters. The oil production of the well tested around 1,320 barrels per day. The successful exploration of Lufeng14-4 demonstrated the company's remarkable breakthrough in the exploration area of the Paleogene SystemCand further proved the huge exploration potential of the Paleogene System in the Pearl River Mouth Basin.
November 18, 2014
11:03 EDTMCDMcDonald's January calls active
McDonald's January 95 calls are active on total call volume of 7700 contracts compared to its open interest of one contract. November call option implied volatility is at 16, December is at 15, January is at 13; compared to its 26-week average of 15 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
November 17, 2014
16:24 EDTCLDXOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
12:48 EDTCLDXCelldex volatility decreases after positive interim update
Celldex November call option implied volatility is at 69, December is at 65, January is at 64; compared to its 26-week average of 73 according to Track Data, suggesting decreasing price movement after the company on Friday afternoon reported interim positive data for its brain tumor treatment, rindopepimut.
12:27 EDTCLDXOn The Fly: Midday Wrap
Subscribe for More Information
11:37 EDTCLDXCelldex soars after reporting results from brain tumor treatment study
Subscribe for More Information
11:11 EDTCLDXHigh option volume stocks:
Subscribe for More Information
09:34 EDTCLDXiPath S&P 500 VIX Short-Term Futures are recently up 19c to 28.86
Subscribe for More Information
08:19 EDTCLDXCelldex Rindo data looks like 'home run,' says Cowen
Subscribe for More Information
07:12 EDTCLDXCelldex data better than expected, says Cantor
Cantor believes that data from the Phase II trial of Celldex's rindopepimut in EGFRvIII-positive glioblastoma multiforme patients exceed expectations. The firm thinks the data is likely to trigger a turning point in the shares. Cantor keeps a $33 price target and Buy rating on the stock.
November 14, 2014
16:26 EDTMCDNasdaq clear leader as major averages end week higher
Subscribe for More Information
15:57 EDTCLDXCelldex to meet with FDA, propose accelerated approval filing, Feuerstein says
Subscribe for More Information
15:42 EDTCLDXCelldex sees significant survival benefit in Avastin-naive phase 2 trial
Subscribe for More Information
12:58 EDTMCDOn The Fly: Midday Wrap
Subscribe for More Information
10:16 EDTMCDMcDonald's up 2% after activist JANA reports new stake
Shares of McDonald's are up after 1% after activist investor JANA Partners reported a new 842K share stake in the fast food giant. JANA this morning disclosed its quarterly holdings as of September 30 to the SEC. The stake was acquired between June 30 and September 30 of this year. Shares of McDonald's are up 2%, or $1.63, to $97.11 in early trading.
09:38 EDTMCDJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
09:37 EDTMCDJANA reports new stakes in McDonald's, AECOM, Amgen
Subscribe for More Information
November 13, 2014
10:02 EDTHONHoneywell selected as production aircraft engine supplier for AirLand Scorpion
Subscribe for More Information
08:36 EDTCLDXCelldex to host conference call
Subscribe for More Information
07:10 EDTCLDXSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 12, 2014
16:01 EDTMCDMcDonald's to enter Kazakhstan in 2015
Subscribe for More Information
11:17 EDTCLDXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:05 EDTHONGoldman to hold a conference
Subscribe for More Information
05:19 EDTHONHoneywell supports environmental commitments announced by Presidents Obama, Xi
Honeywell stated, "We applaud the environmental commitments that President Obama and President Xi announced. Governments need to take meaningful steps to reduce and prevent environmental degradation to our air and communities. That is what President Obama and President Xi did. Honeywell is ready to support the broad adoption of the goals that the leaders of the world's biggest economies outlined today. Sustainable development - that includes clean air and communities - is a key building block to stronger economies around the world over the long-term. Establishing emissions reduction commitments, like the ones highlighted by President Obama and President Xi, are critical to the success of healthier global environments. The leadership demonstrated by both the U.S. and China in outlining specific goals is an important step in the right direction and we applaud both countries for their positive commitments. Technologies exist today that will help companies and government make tremendous strides immediately. Honeywell will do our part to provide the products and technologies and to reduce even further our own emissions. We should all stand ready to use existing technologies, while also continuing to innovate for a brighter future."
November 11, 2014
15:43 EDTCLDXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
05:56 EDTMCDMcDonald's recalls Hello Kitty themed whistles due to choking hazards
McDonald's is recalling about 2.3M “Hello Kitty Birthday Lollipop” Whistles in the U.S. and about 200,000 in Canada. The CPSC says components inside of the whistle can detach, posing choking and aspiration hazards to young children. McDonald’s has received two reports of children who coughed out pieces of the whistle that they had sucked into their mouths, including one child who received medical attention. Reference Link
November 10, 2014
16:28 EDTCLDXOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
08:00 EDTMCDMcDonald's reports October APMEA comparable sales down 4.2%
Subscribe for More Information
07:59 EDTMCDMcDonald's reports October Europe comparable sales down 0.7%
Subscribe for More Information
07:59 EDTMCDMcDonald's reports October US comparable sales down 1%
The company said, "To restore business momentum, the U.S. is revamping its marketing approach, simplifying the menu and creating a new organizational structure. These initiatives are designed to better address consumer preferences and the competitive dynamics of the local markets in which we compete by bringing decision making closer to our customers."
07:58 EDTMCDMcDonald's reports October global comparable sales down 0.5%
Subscribe for More Information
05:45 EDTHONHoneywell to boost refinery operations in Turkey
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use